产品说明书
Tecovirimat
 |
同义名 : | ST-246;SIGA-246;TPOXX |
| CAS号 : | 869572-92-9 | |
| 货号 : | A240633 | |
| 分子式 : | C19H15F3N2O3 | |
| 纯度 : | 98% | |
| 分子量 : | 376.329 | |
| MDL号 : | MFCD11973644 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(279.01 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Tecovirimat is a potent, selective and orally bioavailable antipoxvirus compound active against multiple orthopoxviruses, including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), and variola viruses, with EC50 value of 0.01μM for Vaccinia virus in CPE assays. It inhibited plaque formation, virus-induced CPE and extracellular virus production at 5μM. Treatment with oral administration of Tecovirimat, at dose of 50 mg/kg twice a day for 14 days, protected BALB/c mice from lethal infection by vaccinia virus strain IHD-J, A/NCr mice from lethal infection by ectromelia virus[4]. Tecovirimat is FDA-approved for the treatment of human smallpox disease caused by Variola virus in adults and children[5]. | ||
| 作用机制 | Tecovirimat blocks interaction of p37 with Rab9 and TIP47. Thus, ST-246 prevents wrapping complex formation by inhibiting interaction of p37 with components of LE-transport vesicle biogenesis[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.66mL 0.53mL 0.27mL |
13.29mL 2.66mL 1.33mL |
26.57mL 5.31mL 2.66mL |
| 参考文献 |
|---|